Volume 44, Issue 6, Pages (June 2016)

Slides:



Advertisements
Similar presentations
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Advertisements

Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era  Geoffrey A. Preidis, James.
Immunotherapy of hepatocellular carcinoma
Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies  Jose R. Conejo-Garcia, Melanie R. Rutkowski 
Duane R. Wesemann, Cathryn R. Nagler  Immunity 
CD5: A New Partner for IL-6
Cancer Immunotherapy by Dendritic Cells
Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era  Geoffrey A. Preidis, James.
Gut Microbiota: A Natural Adjuvant for Vaccination
Oncology Meets Immunology: The Cancer-Immunity Cycle
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Some interesting science…
Toll-like Receptors Keep Antigen Sorting on the Right Track
Interleukin-18: The Bouncer at the Mucosal Bar
Malaria Vaccine Design: Immunological Considerations
Colorectal cancer vaccines: Principles, results, and perspectives
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Laurence Zitvogel, Guido Kroemer  Cancer Cell 
Dendritic Cells Break Bonds to Tolerize
Essential Role for Oxidative Phosphorylation in Cancer Progression
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
The Intestinal Immune System in Obesity and Insulin Resistance
Intracellular Pathogens and CD8+ Dendritic Cells: Dangerous Liaisons
Getting the Skinny on CD4+ T Cell Survival in Fatty Livers
Robert J Korst, MD, Ronald G Crystal, MD 
Gut Microbiota and Pancreatic Cancer
Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation
Common TLR5 Mutations Control Cancer Progression
BTLA+ Dendritic Cells: The Regulatory T Cell Force Awakens
Host Immune Response to Infection and Cancer: Unexpected Commonalities
Etiology of Type 1 Diabetes
Bridging immunity and lipid metabolism by gut microbiota
Microbiome and Anticancer Immunosurveillance
An IL-1β-Dependent Switch in Innate Mucosal Immunity?
Turning Tumors into Vaccines: Co-opting the Innate Immune System
D. Garrett Brown, June L. Round  Cell 
Thomas S. Griffith, Thomas A. Ferguson  Immunity 
Volume 33, Issue 4, Pages (October 2010)
Maya Saleh, Charles O. Elson  Immunity 
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Volume 39, Issue 1, Pages (July 2013)
Interleukin-18: The Bouncer at the Mucosal Bar
Role of the Microbiota in Immunity and Inflammation
Translating Inflammatory Bowel Disease Research into Clinical Medicine
The Role of TIM-4 in Food Allergy
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Decoding Cell Death Signals in Inflammation and Immunity
Homeostasis and Inflammation in the Intestine
Shifting the Evolving CAR T Cell Platform into Higher Gear
Wenjun Ouyang, Anne O’Garra  Immunity 
Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System  Thomas Siegmund Postler, Sankar Ghosh  Cell Metabolism 
Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance  Ankur Singh, Ilana Brito, Jan Lammerding 
Deciphering and Reversing Tumor Immune Suppression
Professional Differences in Antigen Presentation to iNKT Cells
Andy J. Minn, E. John Wherry  Cell 
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Sterile Inflammation Fuels Gastric Cancer
NOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance  Laurence Zitvogel, Lorenzo Galluzzi, Mark J. Smyth,
The Biology of Intestinal Immunoglobulin A Responses
Releasing the Brakes on Cancer Immunotherapy
Volume 39, Issue 1, Pages (July 2013)
Volume 44, Issue 6, Pages (June 2016)
Padmanee Sharma, James P. Allison  Cell 
Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases  Louis J. Cohen, Judy H. Cho,
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Two Bugs a NOD Away from Improving Cancer Therapy Efficacy
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Presentation transcript:

Volume 44, Issue 6, Pages 1255-1269 (June 2016) Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors  Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer, Laurence Zitvogel  Immunity  Volume 44, Issue 6, Pages 1255-1269 (June 2016) DOI: 10.1016/j.immuni.2016.06.001 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Major Factors Contributing to Primary Resistance to ICB Therapy Many potential tumor-related, host-related, and environmental factors can explain the degree of heterogeneity seen with ICB immunotherapies. These can be categorized into influences from the tumor microenvironment, endocrine and metabolic factors, environmental factors, and other influences such as age and unfavorable host genetics. Immunity 2016 44, 1255-1269DOI: (10.1016/j.immuni.2016.06.001) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Immune-Checkpoint Blockade Mobilizes the Gut Microbiota to Promote Anti-tumor Immune Responses Uptake of distinct bacterial species (e.g., Bacteroides fragilis and Bifidobacteria) or bacteria-derived products by DCs in the context of ICBs can significantly enhance DC antigen-processing and -presentation functions (i.e., upregulation of costimulatory molecules and antigen-presentation molecules such as CD40 and MHC class II) and ensure DC production of cytokines such as IL-12. Together, this DC activation increases the generation of anti-tumor T cells and increases intratumoral T cell numbers. Alterations in the composition of the gut microbiota can affect host anti-cancer immunity. Blockade of CTLA-4 has also been found to modulate the microbiota composition and the function and integrity of the intestinal mucosal barrier, which could facilitate the immune-mediated therapeutic efficacy of anti-CTLA-4 mAb immunotherapy. Abbreviations are as follows: ICB, immune-checkpoint blockade; CTL, cytotoxic T lymphocyte; Th, T helper; DC, dendritic cell; IEL, intestinal epithelial lymphocyte; IEC, intestinal epithelial cell; IFN, interferon; and IL, interleukin. Immunity 2016 44, 1255-1269DOI: (10.1016/j.immuni.2016.06.001) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Mobilizing the Gut Microbiota to Circumvent Primary Resistance to ICB in Patients Determining the precise microbiome of a given patient is becoming possible with the development of metagenomics, metatranscriptomics, and culturomics platforms. The gathered information from these techniques can be used for selecting an approach that will facilitate a particular cancer immunotherapy. Ancillary therapeutic approaches that can be selected to achieve this might include probiotic formulations, gene products, products containing MAMPs, DIPs, mucosal vaccines, or potentially commensal antigens with molecular mimicry to tumor antigens. Immunity 2016 44, 1255-1269DOI: (10.1016/j.immuni.2016.06.001) Copyright © 2016 Elsevier Inc. Terms and Conditions